Advent Life Sciences

We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.

Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.

As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.

We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.

We are backing exceptional innovation early.

Since the year 2006, Advent-backed companies have brought fourteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A

As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Innovative Life Sciences Companies

Advent Life Sciences LLP 27 Fitzroy Square London W1T 6ES T +44 (0)20 7932 2100 E contact@adventls com Data Protection Policy Legal & Regulatory © 2023 Advent Life Sciences

© Advent Life Sciences